Mineralys Therapeutics, Inc. MLYS
Updated: 15 Jun 2026
No signal published yet
We already track Mineralys Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Mineralys Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Mineralys Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In June 2026, Mineralys announced a $150 million stock offering and a $500 million debt facility to fund the repurchase of royalty obligations from Tanabe Pharma. On June 14, 2026, the company presented clinical data at the ENDO 2026 meeting showing that lorundrostat significantly reduced heart failure risk biomarkers in patients with uncontrolled hypertension.
What Firelda Watch includes for Mineralys Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Mineralys Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Mineralys Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more